Real-world safety profile of the 9-valent human papillomavirus vaccine: A study in Zhejiang, China from 2019 to 2021

References

• de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–6. doi:10.1002/ijc.30716. PMID: 28369882.
   PubMed Web of Science ®Google Scholar
• Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121(3):621–32. doi:10.1002/ijc.22527. PMID: 17405118.
   PubMed Web of Science ®Google Scholar
• Yin F, Wang Y, Chen N, Jiang D, Qiu Y, Wang Y, Yan M, Chen J, Zhang H, Liu Y. A novel trivalent HPV 16/18/58 vaccine with anti-HPV 16 and 18 neutralizing antibody responses comparable to those induced by the Gardasil quadrivalent vaccine in rhesus macaque model. Papillomavirus Res. 2017;3:85–90. doi:10.1016/j.pvr.2017.02.005. PMID: 28720462.
   PubMed Web of Science ®Google Scholar
• Baxter P. Pertussis vaccine encephalopathy: ‘oh! Let us never, never doubt. Dev Med Child Neurol. 2010;52(10):883–84. doi:10.1111/j.1469-8749.2010.03781.x. PMID: 21175453.
   PubMed Web of Science ®Google Scholar
• Jegede AS. What led to the Nigerian boycott of the polio vaccination campaign? PLoS Med. 2007;4(3):e73. doi:10.1371/journal.pmed.0040073. PMID: 17388657.
   PubMed Web of Science ®Google Scholar
• Moreira ED Jr, Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, et al. Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 phase III clinical trials. Pediatrics. 2016;138(2). doi: 10.1542/peds.2015-4387. PMID: 27422279.
   PubMed Web of Science ®Google Scholar
• Beavis A, Krakow M, Levinson K, Rositch AF. Reasons for lack of HPV vaccine initiation in NIS-teen over time: shifting the focus from gender and sexuality to necessity and safety. J Adolesc Health. 2018;63(5):652–56. doi:10.1016/j.jadohealth.2018.06.024. PMID: 30348283.
   PubMed Web of Science ®Google Scholar
• Gilkey MB, Mohan D, Janssen EM, McRee AL, Kornides ML, Bridges JFP. Exploring variation in parental worries about HPV vaccination: a latent-class analysis. Hum Vaccin Immunother. 2019;15(7–8):1745–51. doi:10.1080/21645515.2019.1574157. PMID: 30951396.
   PubMed Web of Science ®Google Scholar
• Karafillakis E, Larson HJ, consortium A. The benefit of the doubt or doubts over benefits? A systematic literature review of perceived risks of vaccines in European populations. Vaccine. 2017;35(37):4840–50. doi:10.1016/j.vaccine.2017.07.061. PMID: 28760616.
   PubMed Web of Science ®Google Scholar
• Nordic Cochrane Centre. Complaint to the European Medicines Agency (EMA) over maladministration at the EMA. [ accessed 2022 Nov 30]. https://www.deadlymedicines.dk/wp-content/uploads/2019/02/10.-2016-05-26-Complaint-to-EMA-over-EMAs-handling-of-safety-of-the-HPV-vaccines.pdf
   Google Scholar
• Alicino C, Merlano C, Zappettini S, Schiaffino S, Della Luna G, Accardo C, Gasparini R, Durando P, Icardi G. Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety. Hum Vaccin Immunother. 2015;11(1):91–94. doi:10.4161/hv.34360. PMID: 25483520.
   PubMed Web of Science ®Google Scholar
• Hu Y, Liang H, Wang Y, Chen Y. Inequities in childhood vaccination coverage in Zhejiang, Province: evidence from a decomposition analysis on two-round surveys. Int J Environ Res Public Health. 2018;15(9):2000. doi:10.3390/ijerph15092000. PMID: 30217080.
   PubMed Web of Science ®Google Scholar
• Hu Y, Pan X, Shen L, Chen F, Wang Y, Liang H, Chen Y, Lv H. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine using the national adverse event following immunization surveillance system from Zhejiang province, 2018–2020. Hum Vaccin Immunother. 2021;17(12):5447–53. doi:10.1080/21645515.2021.1978793. PMID: 34613883.
   PubMed Web of Science ®Google Scholar
• Pan X, Lv H, Chen F, Wang Y, Liang H, Shen L, Chen Y, Hu Y. Analysis of adverse events following immunization in Zhejiang, China, 2019: a retrospective cross-sectional study based on the passive surveillance system. Hum Vaccin Immunother. 2021;17:3823–30. PMID: 34170800.
   PubMed Web of Science ®Google Scholar
• Liu D, Wu W, Li K, Xu D, Ye J, Li L, Wang H. Surveillance of adverse events following immunization in China: past, present, and future. Vaccine. 2015;33(32):4041–6. doi:10.1016/j.vaccine.2015.04.060. PMID: 25936727.
   PubMed Web of Science ®Google Scholar
• Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796–803. doi:10.7150/ijms.6048. PMID: 23794943.
   PubMed Web of Science ®Google Scholar
• Shimabukuro TT, Su JR, Marquez PL, Mba-Jonas A, Arana JE, Cano MV. Safety of the 9-valent human papillomavirus vaccine. Pediatrics. 2019;144(6). doi:10.1542/peds.2019-1791. PMID: 31740500.
   PubMed Web of Science ®Google Scholar
• Bonaldo G, Vaccheri A, D’Annibali O, Motola D. Safety profile of human papilloma virus vaccines: an analysis of the US vaccine adverse event reporting system from 2007 to 2017. Br J Clin Pharmacol. 2019;85(3):634–43. doi:10.1111/bcp.13841. PMID: 30569481.
   PubMed Web of Science ®Google Scholar
• Joshi J, Das MK, Polpakara D, Aneja S, Agarwal M, Arora NK. Vaccine safety and surveillance for adverse events following immunization (AEFI) in India. Indian J Pediatr. 2018;85(2):139–48. doi:10.1007/s12098-017-2532-9. PMID: 29170922.
   PubMed Web of Science ®Google Scholar
• Dey A, Wang H, Quinn H, Pillsbury A, Glover C, Hickie M, Wood N, Beard F, Macartney K. Surveillance of adverse events following immunisation in Australia annual report, 2019. Commun Dis Intell. 2018;2021:45. doi:10.33321/cdi.2021.45.23. PMID: 33934694.
   Google Scholar
• Shah PD, Calo WA, Gilkey MB, Boynton MH, Alton Dailey S, Todd KG, Robichaud MO, Margolis MA, Brewer NT. Questions and concerns about HPV vaccine: a communication experiment. Pediatrics. 2019;143(2). doi:10.1542/peds.2018-1872. PMID: 30670584.
   Web of Science ®Google Scholar
• Costa AS, Gomes JM, Germani A, da Silva MR, Santos EFS, Soares Junior JM, Baracat EC, Sorpreso ICE. Knowledge gaps and acquisition about HPV and its vaccine among Brazilian medical students. PloS One. 2020;15(3):e0230058. doi:10.1371/journal.pone.0230058. PMID: 32191725.
   PubMed Web of Science ®Google Scholar
• Nzolo D, Ntetani Aloni M, Mpiempie Ngamasata T, Mvete Luemba B, Bazundama Marfeza S, Bothale Ekila M, Nsibu CN, Tona NL. Adverse events following immunization with oral poliovirus in Kinshasa, Democratic Republic of Congo: preliminary results. Pathog Glob Health. 2013;107(7):381–84. doi:10.1179/2047773213Y.0000000113. PMID: 24392682.
   PubMed Web of Science ®Google Scholar
• Wu W, Liu D, Nuorti JP, Li K, Xu D, Ye J, Zheng J, Cao L, Wang H. Deaths reported to national surveillance for adverse events following immunization in China, 2010–2015. Vaccine. 2019;37(9):1182–87. doi:10.1016/j.vaccine.2019.01.009. PMID: 30709723.
   PubMed Web of Science ®Google Scholar
• Yih WK, Kulldorff M, Dashevsky I, Maro JC. A broad safety assessment of the 9-valent human papillomavirus vaccine. Am J Epidemiol. 2021;190(7):1253–59. doi:10.1093/aje/kwab022. PMID: 33558897.
   PubMed Web of Science ®Google Scholar
• Centers for Disease C, Prevention. Syncope after vaccination—United States, January 2005–July 2007. MMWR Morb Mortal Wkly Rep. 2008;57(17):457–60. PMID: 18451756.
   PubMedGoogle Scholar
• Klein NP, Edwards KM, Sparks RC, Dekker CL, Clinical Immunization Safety Assessment N. Recurrent sterile abscesses following aluminium adjuvant-containing vaccines. BMJ Case Rep. 2009;2009. doi:10.1136/bcr.09.2008.0951. PMID: 21686546.
   PubMedGoogle Scholar